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The availability of cofactor tetrahydrobiopterin (BH 4 ) is one of the factors that regulate the activity of nitric oxide synthase (NOS). 1 BH 4 participates in the catalytic cycle of NOS by providing the second electron to the heme of eNOS. In BH 4 deficiency, reduction of molecular oxygen still occurs at the heme site of eNOS, but oxidation of the guanidine nitrogen of larginine is prevented, so that the reduced oxygen comes off the enzyme as superoxide. 2 This phenomenon is known as "eNOS uncoupling". 2, 3 BH 4 is synthesized endogenously by two different pathways: conversion of GTP to BH 4 by GTP cyclohydrolase I (GTPCH I), a rate-limiting enzyme, via the de novo pathway and conversion of sepiapterin to BH 4 involving sepiapterin reductase via the salvage pathway. 1 Supplementation of BH 4 (10 mg/kg/day, IP) prevented hypertension in 5/6 nephrectomized rats. 4 BH 4 synthesis impairment in spontaneously hypertensive rats (SHR) was associated with increased superoxide production. 5 Chronic treatment with BH 4 (10 mg/kg/ day, IP) from age 5 to 16 weeks suppressed the development of hypertension, improved the impaired vascular response to acetylcholine, and reduced superoxide formation in SHR. 5 However, supplementation of the same dose of BH 4 (IP for 15 days) did not prevent adrenocorticotrophic hormone (ACTH)-or dexamethasone-induced hypertension in rats. 6, 7 It is possible that BH 4 is oxidized in the blood stream before it reaches endothelial cells and smooth muscle.
Sepiapterin is taken up by cells and converted to intracellular BH 4 , so it differs from BH 4 administration that acts extracellularly. 1 Incubation with sepiapterin restored endothelial dysfunction in aorta from dexamethasonetreated Sprague-Dawley (SD) rats. 8 In bovine aortic endothelial cells, sepiapterin restored NO release and abolished superoxide production by GTPCH I inhibition, and sepiapterin supplementation (10 mg/kg/day IP for 7 days) Background Glucocorticoid-induced hypertension is associated with imbalance between nitric oxide (NO) and superoxide. One of the pathways that causes this imbalance is endothelial NO synthase (eNOS) uncoupling. In the present study, adrenocorticotrophic hormone (aCTH)-and dexamethasone-treated rats were further treated with sepiapterin, a precursor of tetrahydrobiopterin, or N-nitro-l-arginine (NOLa), an inhibitor of NOS, to investigate the role of eNOS uncoupling in glucocorticoid-induced hypertension.
Methods
Male Sprague-Dawley (SD) rats (n = 7-13/group) were treated with either sepiapterin (5 mg/kg/day, IP) or saline (sham) 4 days before and during aCTH (0.2 mg/kg/day, SC), dexamethasone (0.03 mg/kg/ day, SC), or saline treatment. NOLa (0.4 mg/ml in drinking water) was given to rats 4 days before and during dexamethasone treatment. Systolic blood pressure (SBP) was measured by the tail-cuff method.
results
Both aCTH (116 ± 2 to 135 ± 3 mm Hg (mean ± s.e.m.), P < 0.001) and dexamethasone (114 ± 4 to 133 ± 3 mm Hg, P < 0.0005) increased SBP. Sepiapterin alone did not alter SBP. Sepiapterin did not prevent aCTH-(129 ± 4 mm Hg, NS) or dexamethasone-induced hypertension (135 ± 3 mm Hg, NS), although plasma total biopterin concentrations were increased. NOLa increased SBP in rats prior to dexamethasone or saline treatment. NOLa further increased SBP in both saline-(133 ± 4 to 157 ± 3 mm Hg, P < 0.05) and dexamethasone-treated rats (135 ± 5 to 170 ± 6 mm Hg, P < 0.05). aCTH and dexamethasone increased plasma F 2 -isoprostane concentrations. Neither sepiapterin nor NOLa significantly affected this marker of oxidative stress.
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Sepiapterin and NOLA in Glucocorticoid Hypertension reversed GTPCH I gene silencing-induced elevation of BP in wild-type mice but had no effect on BP in eNOS −/− mice. 9 Therefore, sepiapterin was used in the present study to further evaluate the role of eNOS uncoupling in glucocorticoidinduced hypertension.
The synthetic glucocorticoid dexamethasone inhibits the expression of iNOS 10 and eNOS 11 as well as eNOS activity. 11 In addition, ACTH, which stimulates endogenous glucocorticoid secretion, also downregulates iNOS and eNOS mRNA expression and stability in renal cortex and medulla, as well as renal tubular eNOS protein levels. 12 Plasma NOx concentrations were reduced by both ACTH 6,13 and dexa methasone. 11 The direct NO donor isosorbide dinitrate reversed ACTHinduced hypertension in the rat 14 and the NOS inhibitor, N-nitro-l-arginine (NOLA), decreased NO production, abolished the preventative effect of l-arginine on ACTHinduced hypertension, 13 and exacerbated ACTH-induced hypertension. 15 Therefore, glucocorticoid-induced hypertension is associated with NO deficiency. The effect of NOLA on dexamethasone-induced hypertension is unknown. If eNOS uncoupling does not play a major role in dexamethasoneinduced hypertension, NOLA should increase blood pressure by decreasing NO production.
Oxidative stress is increased in both ACTH-and dexamethasone-induced hypertension. 16, 17 Antioxidants/anti-inflammatory agents such as tempol, apocynin, N-acetylcysteine, folic acid, and aspirin prevent and reverse ACTH-and/or dexamethasone-induced hypertension. 6, 16, [17] [18] [19] Superoxide anion can act as a NO scavenger and reduce NO bioavailability. Therefore, eNOS uncoupling phenomenon could be a cause of decreased NO and increased reactive oxygen species.
Dexamethasone inhibits cytokine-stimulated expression of GTPCH I in rat endothelial cells 20 and renal mesangial cells, 21 induces endothelial dysfunction, and suppresses GTPCH I gene expression in isolated rat aortic rings 8 and mouse skin. 22 Incubation with sepiapterin can restore endothelial dysfunction in aorta of dexamethasone-treated rats. 8 Based on these in vitro studies, it has been postulated that GTPCH I downregulation contributes to glucocorticoid hypertension in rats. 23 The aim of this study was to investigate the role of eNOS uncoupling in ACTH and dexamethasone-induced hypertension using sepiapterin and NOLA.
Methods
Animals. Male SD rats (body weight range from 200 to 250 g) were housed in individually ventilated cages under controlled temperature (21-23 °C), humidity (57%), and lighting (12-h alternating light-dark cycle). Rats were housed communally in groups of 2-3 rats/cage and had free access to rat chow and tap water. Animals were allowed at least 1 week to acclimatize to the environment, handling, and blood pressure measuring equipment prior to any experimental procedure. This study was approved by the Animal Experimental Ethics Committee of the Australian National University (J. HB. 28.07).
Chemicals ACTH (Novartis Pharmaceuticals, Sydney, Australia) or dexamethasone (David Bull Laboratories, Mulgrave, Australia) was diluted in physiological saline and injected subcutaneously (SC) daily. Sepiapterin (Schircks Laboratories, Jona, Switzerland) was diluted in physiological saline and administered to rats by intraperitoneal (IP) injection. NOLA (Sigma-Aldrich, St Louis, MO) was added to drinking water. Isoflurane (Isoflo Vetl Abbott Laboratories, Kent, UK) was used to anesthetize rats during culling.
Experimental protocol. Our previous studies show that both ACTH (0.2 mg/kg/day SC) and dexamethasone (0.03 mg/ kg/day SC) raised blood pressure within 2 days and blood pressure reaches its peak around 8 days of treatment. 6, 7, [15] [16] [17] [18] Therefore, the same dosage regimes and times were used in the current study. Sepiapterin (5 mg/kg/day IP 30 min before ischemia) protected ischemic/reperfusion injury in mice. 24 This dose and method of sepiapterin was used in the current study. NOLA (0.4 mg/ml) was given in the drinking water as previously described. 13 Sepiapterin or NOLA pretreatment days were defined as "P. " ACTH, dexamethasone, and saline treatment days were defined as "T. " The rats were randomly assigned to one of the following groups:
Sepiapterin studies:
Group 1: sham treatment (n = 12): saline, vehicle for ACTH and dexamethasone, was injected SC daily for 11 days (T0-T10); and saline, vehicle for sepiapterin, was given IP throughout the study.
Group 2: ACTH only treatment (n = 12): ACTH SC from T0 to T10 and saline IP injection from P0 to T10.
Group 3: dexamethasone only treatment (n = 13): dexamethasone SC from T0 to T10 and saline IP injection from P0 to T10.
Group 4: sepiapterin + saline treatment (n = 10): rats were treated with sepiapterin IP for 4 days (P0-P3) prior to and during saline SC co-treatment for 11 days (T0-T10).
Group 5: sepiapterin + ACTH treatment (n = 10): rats were treated with sepiapterin IP for 4 days prior to and during ACTH SC co-treatment from T0 to T10.
Group 6: sepiapterin + dexamethasone treatment (n = 10): rats were treated with sepiapterin IP for 4 days prior to and during dexamethasone SC co-treatment from T0 to T10.
NOLA study:
Group 1: saline alone treatment (n = 8): saline injection daily from T0 to T10 and untreated tap water to drink throughout the study.
Group 2: dexamethasone alone treatment (n = 8): dexamethasone was given daily from T0 to T10 and untreated tap water to drink throughout the study.
Group 3: NOLA + saline treatment (n = 7): rats were given NOLA via drinking water for 4 days (P0-P3) prior to and during saline co-treatment for 11 days (T0-T10).
Group 4: NOLA + dexamethasone treatment (n = 7): rats were given NOLA via drinking water for 4 days prior to and during dexamethasone co-treatment for 11 days.
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SBP and body weight measurements. Systolic blood pressure (SBP) was recorded on alternate days by the tail-cuff method (version 1.0; SDR Clinical Technology, Sydney, Australia) in conscious rats. Rats were restrained inside clear Perspex rat restrainers and placed on a preheated base plate (38-40 °C) for ~35 min. Several SBP readings were recorded for each rat and four median SBP readings, in which difference was within 10 mm Hg, were averaged. The average of four median readings was used as mean SBP. Body weight was measured on alternate days after SBP measurement.
Thymus weight. At the end of the experiment, rats were killed under anesthesia (4% isoflurane). Thymus wet weight was measured as a marker of glucocorticoid activity 25 and expressed relative to body weight (mg thymus wet weight per 100 g of body weight).
Plasma total biopterin concentrations. Blood was collected into chilled tubes containing EDTA and ascorbic acid (100 mg/ ml). After centrifuge at 4 °C, plasma was obtained and stored at −70 °C. Plasma total biopterin concentration was measured using high performance liquid chromatography after iodine oxidation of BH 4 as previously described. 7 Plasma NOx concentrations. Plasma NOx concentration, a biomarker for NO production, was measured using the Griess colorimetric reaction in a commercially available kit (Endogen; Pierce Biotechnology, Rockford, IL) as previously described. 16 Plasma F2-isoprostane concentrations. Blood was collected into chilled tubes containing EDTA, reduced glutathione, and butylated hydroxytoluene. Plasma was stored at −70 °C until assay. Plasma F 2 -isoprostanes were measured using electroncapture negative-ion gas chromatography-mass spectrometry as previously described. 26 Data and statistical analysis. Data were presented as mean ± s.e.m. except for plasma NOx data that were presented as median. Biochemical data from saline-treated rats and dexamethasone-treated rats of both studies were pooled for Figure 3a,c,d and relevant statistical analysis. Statistical analysis was performed using SPSS software (version 15.0; SPSS, Chicago, IL). Comparisons were performed using repeated measures analysis of variance (RM-ANOVA) with Greenhouse-Geisser adjustment for multisample asphericity or independent t-test. The Ryan-Holm step-down Bonferroni procedure was used to minimize the family-wise type I error rate. The convention that adjusted P′ ≤ 0.05 should be regarded as "significant" was adopted. 27 results effects of sepiapterin on sBP SBP of sham-treated rats was unchanged (114 ± 3 T0 to 119 ± 3 mm Hg T10) (Figure 1 ) but raised in ACTH-treated rats (116 ± 2 T0 to 135 ± 3 mm Hg T10, P < 0.001, one-way RM-ANOVA) (Figure 1a) and dexamethasone-treated rats (114 ± 4 T0 to 133 ± 3 mm Hg T10, P < 0.0005, one-way RM-ANOVA) (Figure 1b) . Sepiapterin alone did not alter SBP (Figure 1) . The combination of sepiapterin and saline treatment did not alter SBP (110 ± 3 T0 to 119 ± 3 mm Hg T10). Sepiapterin did not prevent the rise in SBP caused by either ACTH (110 ± 3 T0 to 129 ± 4 mm Hg T10, P < 0.001, oneway RM-ANOVA) or dexamethasone (112 ± 3 T0 to 135 ± 3 mm Hg T10, P < 0.0005, one-way RM-ANOVA). SBP of both ACTH-and dexamethasone-treated rats was significantly higher relative to saline-treated rats (P′ <0.005 for each, twoway RM-ANOVA). There was no difference in SBP between ACTH and sepiapterin+ACTH, and dexamethasone and sepiapterin+dexamethasone-treated rats.
effects of nola on sBP
Daily saline injection did not alter SBP (121 ± 4 T0 to 128 ± 5 mm Hg T10, one-way RM-ANOVA) (Figure 2) . In dexamethasone-treated rats, SBP increased from 123 ± 6 mm Hg on T0 to 144 ± 3 mm Hg on T10 (P < 0.05, one-way RM-ANOVA) (Figure 2) . Before dexamethasone treatment, NOLA alone increased SBP in both saline-and dexamethasone-treated rats. SBP in NOLA-and saline-treated rats was significantly increased (133 ± 4 T0 to 157 ± 3 mm Hg T10, P < 0.05, oneway RM-ANOVA). In NOLA/dexamethasone-treated rats, SBP increased from 135 ± 5 T0 to 170 ± 6 mm Hg T10 (P < 0.05, one-way RM-ANOVA). Relative to saline-treated rats, SBP was significantly higher in dexamethasone-treated rats (P′ < 0.05, two-way RM-ANOVA). NOLA increased SBP in both saline (P′ < 0.05, two-way RM-ANOVA) and dexamethasone-treated rats (P′ < 0.05, two-way RM-ANOVA) compared with saline-treated rats.
Body weight
Body weight was lower in saline+dexamethasone-treated rats (277 ± 9 T0 to 278 ± 7 g T10), dexamethasone-treated rats (296 ± 6 to 290 ± 9 g), and ACTH-treated rats (275 ± 11 to 267 ± 9 g) compared with saline-treated rats (296 ± 6 to 331 ± 7 g, P < 0.05, two-way RM-ANOVA). Neither sepiapterin nor NOLA had significant effect on body weight in ACTH-, dexamethasone-, or saline-treated rats.
thymus weight
Thymus weight was significantly lower in ACTH-and dexamethasone-treated rats compared with saline-treated rats. Neither sepiapterin nor NOLA had an effect on thymus weight (Figure 3a) .
daily water consumption
Daily water consumption was not altered by dexamethasone alone (34.0 ± 0.8 ml) compared with saline alone-treated rats (36 ± 1 ml) (NS, independent t-test with Bonferroni). In saline-treated animals, water intake was higher in rats treated with NOLA-(42 ± 1 ml) than with tap water (36 ± 1 ml) (P′ = 0.015, independent t-test with Bonferroni). However, increased water intake was not observed in dexamethasone-treated rats (34 ± 1 ml, dexamethasone alone original contributions Sepiapterin and NOLA in Glucocorticoid Hypertension vs. 37 ± 1 ml, NOLA+dexamethasone) (NS, independent t-test with Bonferroni).
Plasma total biopterin concentrations
Plasma total biopterin concentrations were 57 ± 9 nmol/l for sham-treated rats. Neither ACTH (50 ± 8 nmol/l) nor dexamethasone (41 ± 9 nmol/l) affected plasma total biopterin concentrations. Plasma total biopterin concentrations were increased in sepiapterin-treated rats (613 ± 114 nmol/l for sepiapterin+saline, 263 ± 53 nmol/l for sepiapterin+ACTH, and 446 ± 164 for sepiapterin+dexamethasone) compared with sham-treated rats (Figure 3b) .
Plasma nox concentrations
Plasma NOx concentrations of one animal treated with NOLA+saline and three animals treated with NOLA+dexamethasone were undetectable (Figure 3c ). There was a trend toward decrease in median of plasma NOx concentrations in both groups treated with NOLA (4.1 µmol/l) compared to sham-treated rats (7.4 µmol/l in saline and 6.7 µmol/l in dexamethasone). However, there was a large variation in response to NOLA-treated rats and therefore difficult to see a significant difference in plasma NOx concentrations between treatment groups.
Plasma F 2 -isoprostane concentrations
Plasma F 2 -isoprostane concentrations tended to be higher in ACTH-treated rats (4196 ± 342 pmol/l) and significantly higher in dexamethasone-treated rats (4597 ± 188 pmol/l, P′ = 0.030, independent t-test with Bonferroni) compared to saline-treated rats (3711 ± 333 pmol/l). Sepiapterin had effect on plasma F 2 -isoprostane concentrations (Figure 3d) . In dexamethasone-but not saline-treated rats, there was a near significant increase in plasma F 2 -isoprostane concentrations in NOLA+dexamethasone-treated rats compared with dexamethasone alone-treated rats (P = 0.0662, independent t-test).
discussion
The major findings of these studies were that (i) administration of sepiapterin did not prevent either ACTH-or dexamethasone-induced hypertension, although it did increase plasma total biopterin concentrations; and (ii) inhibition of NOS with NOLA exacerbated dexamethasone-induced hypertension.
Previous studies showed that plasma NOx concentrations were reduced in both ACTH-and/or dexamethasone-treated rats. 6, 11, 16, 28, 29 However, this marker of NO production was not affected by ACTH, dexamethasone, or NOLA in the present study in which plasma NOx concentrations of the control group were very low making detection of further decrease difficult. On the other hand, plasma NOx concentrations may not reflect changes of NO at the tissue level. The same limitation applies for using plasma total biopterin and F 2 -isoprostane concentrations as indirect markers for BH 4 bioavailability and oxidative stress, respectively.
Previous studies demonstrated that oxidative stress is increased in ACTH-and dexamethasone-induced hypertension. 18, 20, 30 In addition, the superoxide scavenger tempol original contributions Sepiapterin and NOLA in Glucocorticoid Hypertension and the NADPH oxidase inhibitor apocynin have been shown to prevent and reverse ACTH-and dexamethasone-induced hypertension. 20, 22, 31, 32 In the present study, both ACTH and dexamethasone increased plasma F 2 -isoprostane concentrations that are consistent with our previous findings. Sepiapterin did not affect this marker of oxidative stress. Sepiapterin abolished superoxide production by GTPCH I inhibition in bovine aortic endothelial cells. 9 The lack of effect of sepiapterin on plasma F 2 -isoprostane concentrations suggest eNOS uncoupling may not play a major role in glucocorticoid-induced oxidative stress. In dexamethasone-but not saline-treated rats, there was a near significant increase in plasma F 2 -isoprostane concentrations in NOLA+Dex-treated rats compared with dexamethasone alonetreated rats indicating there is increased oxidative stress when NOS was inhibited. Dexamethasone-induced hypertension is associated with NO deficiency. 10, 11 NOLA may further reduce NO production in dexamethasone-treated rats if NOS is not uncoupled. With less NO to react with superoxide, oxidative stress may increase.
Uncoupled eNOS due to BH 4 deficiency results in reduction of NO and increased superoxide production in aortic segments of deoxycorticosterone acetate-salt hypertensive mice and in consequence, hypertension. 33 In the absence of BH 4 , supplementation of l-arginine increased superoxide production from eNOS in vitro. 34 However, supplementation of l-arginine prevented and partially reversed ACTH-induced hypertension 13, 28, 29 and did not worsen dexamethasone-induced hypertension. 32, 35 In addition, the effect of l-arginine itself was reversed by the administration of NOLA, a NOS inhibitor. 29 In the present study, we demonstrated that NOLA exacerbated dexamethasone-induced hypertension in SD rats. The SBP increase in NOLA+dexamethasone-treated rats (42 mm Hg) is consistent with an additive effect of dexamethasone (16 mm Hg) and NOLA (29 mm Hg). These data are consistent with the effect of NOLA on ACTH-induced hypertension. 15 In the current study, we demonstrated that supplementation of sepiapterin increased plasma total biopterin concentrations but had no effect on ACTH-and dexamethasone-induced hypertension. These results are consistent with previous findings that supplementation of BH 4 to SD rats did not prevent ACTH 7 and dexamethasone-induced hypertension, although plasma total biopterin concentrations were increased. 6 In conclusion, supplementation of sepiapterin did not prevent ACTH-and dexamethasone-induced hypertension and NOLA exacerbated dexamethasone-induced hypertension. Based on in vitro studies, 8, [20] [21] [22] it has been postulated that GTPCH I downregulation contributes to glucocorticoid 
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Sepiapterin and NOLA in Glucocorticoid Hypertension hypertension in rats. 23 However, data from the current study, together with our previous findings that eNOS expression was decreased in glucocorticoid-induced hypertension, 15 BH 4 supplementation did not affect glucocorticoid-induced hypertension, 10,11 l-arginine partially prevented and reversed ACTH-induced hypertension 13, 28, 29 and did not worsen dexamethasone-induced hypertension, 32, 35 and NOLA exacerbated ACTH-induced hypertension, 15 indicate that eNOS uncoupling does not play a major role in glucocorticoidinduced hypertension in the rat.
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